

BRIEF CONCLUSIVE REPORT

DEK, a nuclear protein, is chemotactic for hematopoietic stem/progenitor cells acting through CXCR2 and G α i signaling

Maegan L. Capitano¹ | Yasser Sammour¹ | James Ropa¹ | Maureen Legendre² | Nirit Mor-Vaknin² | David M. Markovitz²

¹ Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, Indiana, USA

² Department of Internal Medicine, Division of Infectious Diseases, University of Michigan, Ann Arbor, Michigan, USA

Correspondence

Maegan L. Capitano, Department of Microbiology and Immunology, Indiana University School of Medicine, 635 Barnhill Drive, MS 420, Indianapolis, IN 46202, USA.
Email: mlcapit@iupui.edu

Abstract

Few cytokines/growth modulating proteins are known to be chemoattractants for hematopoietic stem (HSC) and progenitor cells (HPC); stromal cell-derived factor 1 α (SDF1 α /CXCL12) being the most potent known such protein. DEK, a nuclear DNA-binding chromatin protein with hematopoietic cytokine-like activity, is a chemotactic factor attracting mature immune cells. Transwell migration assays were performed to test whether DEK serves as a chemotactic agent for HSC/HPC. DEK induced dose- and time-dependent directed migration of lineage negative (Lin⁻) Sca-1⁺ c-Kit⁺ (LSK) bone marrow (BM) cells, HSCs and HPCs. Checkerboard assays demonstrated that DEK's activity was chemotactic (directed), not chemokinetic (random migration), in nature. DEK and SDF1 α compete for HSC/HPC chemotaxis. Blocking CXCR2 with neutralizing antibodies or inhibiting G α i protein signaling with Pertussis toxin pretreatment inhibited migration of LSK cells toward DEK. Thus, DEK is a novel and rare chemotactic agent for HSC/HPC acting in a direct or indirect CXCR2 and G α i protein-coupled signaling-dependent manner.

KEYWORDS

chemokines, chemotaxis, CXCR2, DEK, G α i signaling, hematopoietic stem and progenitor cells

1 | INTRODUCTION

Nuclear protein DEK, a nonhistone chromosomal factor, is vital for global heterochromatin integrity, transcription, DNA repair, and gene regulation,¹⁻³ and post-translational modifications of DEK greatly influence its function.⁴⁻⁷ Disassociation of phosphorylated DEK from chromatin, and thus the nucleus, allows its secretion by hematopoietic

cells in free form or in exosomes by IL-8-stimulated monocyte-derived macrophages in a CK2-dependent and Golgi-apparatus-independent manner.^{8,9} Poly-ADP-ribosylation of DEK allows for its passive secretion by T cells undergoing apoptosis.⁷ Secreted DEK is associated with autoimmune diseases such as juvenile idiopathic arthritis, sarcoidosis, and systemic lupus erythematosus.^{2,9,10} In autoimmune arthritis, autoantibodies against DEK and DEK itself are detected in synovial fluid of arthritic joints and are required for maximum inflammatory cell recruitment into joint tissue.^{9,11,12} Secreted DEK, in free form, is a chemoattractant for neutrophils, CD8⁺ T lymphocytes, and NK cells.^{9,11}

Both endogenous DEK and extracellular, recombinant DEK regulate hematopoiesis.^{2,9,13-16} Endogenous, nuclear DEK is required for the

Abbreviations: AKT, protein kinase B; BM, bone marrow; C/EBP α , CCAAT enhancer binding protein α ; CK2, casein kinase 2; EKLF, erythroid Kruppel-like factor; HPC, hematopoietic progenitor cell; HSC, hematopoietic stem cell; IUSM, Indiana University School of Medicine; Lin⁻, lineage negative; LSK cells, Lin⁻ Sca-1⁺ c-Kit⁺ cells; LT, long-term; MIP2, macrophage inflammatory protein 2; MPP, multipotent progenitor cells; PT, Pertussis toxin; rh, recombinant human; rm, recombinant mouse; SDF1 α , stromal cell-derived factor 1 α ; ST, short-term.

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial](https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

© 2022 The Authors. *Journal of Leukocyte Biology* published by Wiley Periodicals LLC on behalf of Society for Leukocyte Biology.

optimal function of the CCAAT enhancer binding protein (C/EBP) α , a transcription factor that coordinates proliferation arrest and myeloid progenitor cell differentiation into mature myeloid cells.¹⁷ DEK also interacts with upstream enhancer elements of the erythroid Kruppel-like factor (EKLF) promoter, increasing expression of EKLF, a zinc finger transcription factor that plays a role in the global regulation of erythroid gene expression.^{18–22} Thus, endogenous DEK plays a role by maintaining hematopoietic stem cell (HSC) function and regulating myelopoiesis. Moreover, extracellular, recombinant DEK regulates hematopoiesis, enhances *ex vivo* expansion of functional mouse and human HSC, and increases HSC numbers with subsequent decreases in hematopoietic progenitor cell (HPC) numbers and cycling.¹⁶

Very few proteins, SDF1 α /CXCL12 being the most potent, have chemotactic activity for HSC/HPC.^{23,24} We have shown that extracellular DEK suppresses HPC proliferation through a CXCR2-dependent mechanism similarly to the chemokines IL-8 (only expressed in humans) and MIP2.^{9,16,25–27} DEK activates, either directly or indirectly, a CXCR2 signaling cascade in HSC and HPC involving G α i, ERK, protein kinase B (AKT), and p38 MAPK.¹⁶ As DEK is chemotactic for multiple mature hematopoietic cells and regulates hematopoiesis in a CXCR2-dependent manner,^{9,16} we hypothesized that DEK could act as a chemotactic protein for HSC and HPC. We now show that extracellular DEK acts as a rare chemotactic agent for HSC/HPC in a CXCR2- and G α i-dependent manner and competes with SDF1 α /CXCL12 in mediating HSC/HPC migration.

2 | MATERIALS AND METHODS

2.1 | Mice

C57BL/6J mice (6–10 weeks old) obtained from an on-site breeding core facility at Indiana University School of Medicine (IUSM) were maintained under temperature- and light-controlled conditions (21–24°C, 12-h light/12-h dark cycle) and were group-housed according to age and sex, fed *ad libitum*, and matched by age and sex for all experiments. All animal experiments followed protocols approved by the Institutional Animal Care and Use Committee of IUSM.

2.2 | RNA-seq analysis

Raw RNA-sequencing reads have previously been deposited in the Gene Expression Omnibus under accession GSE126875. Reads were aligned and assigned to the mouse genome (mm10) using STAR and HTSeq as previously described.¹⁶ Gene counts were normalized by library size and differential expression analysis was performed comparing mouse Lin[–] bone marrow (BM) treated with recombinant mouse (rm)DEK compared with vehicle-treated cells using DESeq2 R package with the design ~mouse + treatment. Fast gene set enrichment (FGSEA) was performed using fgsea R package to

compare ranked gene list using the test statistic from DESeq2 to rank gene expression differences to a priori defined gene sets from the MSigDB. Fgsea was performed with the following parameters: pathways = c(Mm.C2,Mm.C5,Mm.C6); nperm = 1000; minSize = 25; maxSize = 500. For examining CXCR2 expression levels in mice and humans, microarray normalized log₂ expression value data were downloaded from the BloodSpot (<https://servers.binf.ku.dk/bloodspot/>) database and plotted in GraphPad Prism. Normalization for these data has been previously described.²⁸

2.3 | BM Lin[–] and Ly6G⁺ cell chemotaxis

RmDEK was purified from insect cells as described previously.^{5,14,16} Recombinant DEK was dialyzed prior to its use. BM Lin[–] and Ly6G⁺ cells were prepared as described in Supplemental Materials and Methods. Costar 24-well transwell plates with 6.5 mm diameter inserts with 5.0 μ m pores (Corning Inc, Corning, NY, USA) were used for chemotaxis assays. Prewarmed serum-free IMDM medium (650 μ l) containing recombinant human (rh)SDF1 α (R&D Systems; catalog #350-NS), rmDEK, rhIL-8/CXCL8 (R&D Systems, catalog 208-IL), or rmMIP2/CXCL2 (R&D Systems, catalog #452-M2) at the indicated concentrations were added to the lower and/or upper chamber as indicated. Media alone served as a negative control. Mouse BM Lin[–] or Ly6G⁺ cells (1×10^5 cells/100 μ l) were resuspended in IMDM with 0.5% BSA (Sigma–Aldrich, Miamisburg, OH, USA). Cell suspensions (100 μ l) were placed in the upper chamber of the transwell plate. Transwell plates were placed in a 37°C incubator with 5% CO₂ and 95% humidity for 4 h or indicated time points. Percent migration was determined by flow cytometry as described in Supplemental Materials and Methods. To examine the importance of G α i protein-coupled receptor signaling in DEK-mediated chemotaxis of BM Lin[–] and Ly6G⁺ cells, we incubated Lin[–] and Ly6G⁺ cells from C57BL/6 mice with 1000 ng/ml Pertussis toxin (PT; Sigma–Aldrich; catalog P7208) for 4 h at 37°C immediately prior to the chemotaxis assay. To block CXCR2 and CXCR4 on the cell surface, BM Lin[–] and Ly6G⁺ cells were incubated with 2.5 μ g/10⁶ cells of anti-mouse CXCR2 purified rat monoclonal IgG2A antibody (R&D Systems; clone 242216), anti-mouse CXCR4 purified rat monoclonal IgG2B antibody (R&D Systems; clone 247506), or isotype rat IgG control (azide free; R&D Systems; catalog 6-001-F) for 30 min at room temperature prior to use and cells washed.

2.4 | Statistics

Results are expressed as mean values \pm standard deviation. Two-tailed Student's *t*-test was used where indicated. One-way ANOVA with post-hoc Tukey's multiple-comparisons test was used when comparing 3 or more groups. Statistical analysis was performed using Microsoft Excel and GraphPad Prism 5.0. *p* < 0.05 was considered statistically significant.

TABLE 1 Effects of rmDEK on migration of LSK BM cells as assessed by checkerboard assay (see Figure S2(A) for experimental design)^a

rmDEK concentration (ng/ml) in lower chamber	rmDEK concentration (ng/ml) in upper chamber		
	0	50	100
0	0.55% ± 0.09	0.55% ± 0.15	0.65% ± 0.07
50	20.3% ± 0.83	3.82% ± 0.89 ^b	2.46% ± 0.35 ^b
100	24.4% ± 3.41	6.79% ± 0.69 ^c	5.51% ± 0.71 ^c

^aData represent percent migrating LSK BM cells.

^b $p < 0.01$ when compared with group that had 0 ng/ml rmDEK in top chamber and 50 ng/ml rmDEK in bottom chamber.

^c $p < 0.01$ when compared with group that had 0 ng/ml rmDEK in top chamber and 100 ng/ml rmDEK in bottom chamber.

3 | RESULTS/DISCUSSION

3.1 | HSC/HPC-enriched LSK cells migrate toward rmDEK in a time- and dose-dependent manner

To examine novel functions of rmDEK in HSC and HPC regulation, we reexamined RNA-seq data from our previous study demonstrating that DEK regulates hematopoiesis.¹⁶ A deeper look at this RNA-seq data of pooled mouse BM HSCs and HPCs treated with rmDEK overnight compared with vehicle control-treated cells revealed that gene programs associated with chemotaxis are significantly up-regulated upon treatment with rmDEK (Figure 1(A)). This includes genes associated broadly with cell chemotaxis, genes associated specifically with leukocyte migration, and genes that positively regulate cell–cell adhesion. It is well known that DEK is secreted by macrophages and acts as a proinflammatory molecule serving as a chemotactic factor attracting neutrophils, CD8⁺ T lymphocytes, and NK cells.^{7,9,12} Very few cytokines/chemokines chemotax HSCs/HPCs, SDF1 α /CXCL12 being the most potent of such proteins.^{23,24} To test if extracellular DEK can chemotax HSCs/HPCs, transwell migration assays were performed utilizing Lin⁻ BM cells. LSK cells (enriched in HSCs/HPCs) within the Lin⁻ BM cell population migrated toward 100 ng/ml rmDEK with maximum percent migration reached by 4 h in culture (Figure S1(A)). LSK cells migrated toward rmDEK in a dose-dependent manner, with maximum percent migration (~20%) occurring at equal to or greater than 50 ng/ml rmDEK following both 4 (Figure S1(B)) and 8 h (Figure S1(C)) incubation.

3.2 | rmDEK induces chemotactic, not chemokinetic, movement of LSK cells

Not all factors that influence cellular migration do so in a directional, nonrandom, way (e.g., stem cell factor is chemokinetic for HPC).²⁴ To determine if DEK mediates chemotactic (directional migration toward a chemoattractant gradient) or chemokinetic (random migration) movement of LSK cells, we performed a checkerboard analysis of LSK cell migration (Figures S2(A) and S2(B); Tables 1 and 2). Checkerboard analysis was performed by placing 0–100 ng/ml of rmDEK in the bottom well and 0–100 ng/ml of rmDEK in the insert (top well) of the transwell assay (Figure S2(A)) so that there are wells with different

concentrations of rmDEK on the top and bottom compartments (e.g., 0 ng/ml on top:50 ng/ml on bottom, 50 ng/ml on top: 50 ng/ml on bottom, etc.). If cells still migrate to the bottom well when there is rmDEK in the top well, then the movement is considered random, thus rmDEK most likely would be producing chemokinetic movement. When Lin⁻ cells were placed into media alone in the top well, LSK cells migrated toward the bottom chambers that contained 50 and 100 ng/ml rmDEK (Table 1). However, when rmDEK was added to the top well, LSK cell migration was significantly inhibited suggesting that rmDEK mediates chemotactic, not chemokinetic movement, of LSK cells. To confirm that our checkerboard assays were accurate, we repeated this procedure utilizing rhSDF1 α as a positive control and confirmed that LSK cell migration toward SDF1 α is chemotactic (Figure S2(B) and Table 2).

3.3 | rmDEK induces migration of LT-HSC, ST-HSC, and MPP populations

To determine for which HSC and HPC populations rmDEK acts as a chemoattractant, we first examined LSK and LK (a myeloid progenitor-enriched) cell migration toward rmDEK and rhSDF1 α , the latter as a positive control. LSK and LK cell populations migrated toward rhSDF1 α and rmDEK (Figures 1(B) and 1(C)). Within the LSK population are the long-term (LT)-HSC, short-term (ST)-HSC and multipotent progenitor (MPP) cell populations. LT-HSC, ST-HSC, and MPP all migrated toward rmDEK and rhSDF1 α (Figure 1(D)).

3.4 | DEK is a more potent chemoattractant for LSK cells than is SDF1 α

As both rmDEK and rhSDF1 α induce LSK migration in transwell migration assays, we examined whether one or the other is a more potent chemoattractant when in competition with each other. Checkerboard assays were performed where different concentrations of rmDEK were used in the top well and different concentrations of rhSDF1 α were used on the bottom (Figure S2(C) and Table 3) or vice versa (Figure S2(D) and Table 4). Since rhSDF1 α is an 8 kDa protein and rmDEK is a 43–50 kDa protein, we performed these checkerboard assays using molarity. The addition of 2.5 nM rmDEK to the top insert/well resulted




FIGURE 1 Long-term (LT) hematopoietic stem cell (HSC), short-term (ST)-HSC, and multipotent progenitors (MPP) migrate toward rmDEK. (A) Previously generated RNA-seq data (GSE126875) were reanalyzed for differential gene expression and fast gene set enrichment analysis (FGSEA) was performed using publicly available gene sets from MSigDB. Padj = adjusted p value; ES = enrichment score; NES = normalized enrichment score. (B) Representative flow cytometry analysis of input (Lin⁻ cells) and output samples (Lin⁻ cells migrating toward wells containing media alone, 100 ng/ml recombinant human stromal cell-derived factor 1 alpha [rhSDF1 α], or 100 ng/ml rmDEK) from a 4 h transwell migration assay at 37°C. Plots are of Lin⁻ gated cells. (C) Average percent LSK and myeloid progenitor-enriched Lin⁻ Sca-1⁻ c-Kit⁺ (LK) cells in the input Lin⁻ populations and the migrated cell populations from wells containing media alone, 100 ng/ml rhSDF1 α , or 100 ng/ml rmDEK. Data represent mean \pm SD of 3 replicate wells. Data are representative of 1 of 3 separate experiments. * p < 0.05, ** p < 0.001, and *** p < 0.0001 when compared with percent input population. (D) Migration of LSK cells, LT-HSC (LSK CD150⁺ Flt3⁻), ST-HSC (LSK CD150⁺ Flt3⁺), and MPP (LSK CD150⁻ Flt3⁺) cells toward media alone, 100 ng/ml rhSDF1 α and 100 ng/ml rmDEK. Data represent mean \pm SD of 3 experiments pooled together. * p < 0.05, ** p < 0.01, and *** p < 0.001 when compared with media alone group. (C and D) Statistical significance was determined using one-way ANOVA with post-hoc Tukey's multiple-comparisons test using GraphPad Prism 5.0 software

in significant inhibition of LSK cell migration toward 10 nM SDF1 α (Figure S2(C) and Table 3). However, it took 10 nM SDF1 α to significantly inhibit LSK cell migration toward 10 nM rmDEK (Figure S2(D) and Table 4) suggesting DEK is a more potent chemoattractant for LSK cells.

3.5 | LSK cell migration toward rmDEK is CXCR2- and G α i protein-coupled signaling dependent

Because DEK requires the chemokine receptor CXCR2 to regulate hematopoiesis,^{9,16} we hypothesized that DEK may manifest its

TABLE 2 Effects of rhSDF α on migration of LSK BM cells as assessed by checkerboard assay (see Figure S2(B) for experimental design)^a

rhSDF1 α concentration (ng/ml) in lower chamber	rhSDF1 α concentration (ng/ml) in upper chamber		
	0	50	100
0	0.61% \pm 0.02	0.35% \pm 0.06	0.31% \pm 0.06
50	25.4% \pm 1.94	2.75% \pm 1.26 ^b	2.00% \pm 0.19 ^b
100	27.0% \pm 1.38	8.30% \pm 0.04 ^c	3.16% \pm 1.09 ^c

^aData represent percent migrating LSK BM cells.

^b $p < 0.01$ when compared with group that had 0 ng/ml rhSDF1 α in top chamber and 50 ng/ml rhSDF1 α in bottom chamber.

^c $p < 0.01$ when compared with group that had 0 ng/ml rhSDF1 α in top chamber and 100 ng/ml rhSDF1 α in bottom chamber.

TABLE 3 Checkerboard assay to determine if rmDEK can inhibit the migration of LSK BM cells toward rhSDF1 α (see Figure S2(C) for experimental design)^a

rhSDF1 α concentration (nM) in lower chamber	rmDEK concentration (nM) in upper chamber			
	0	2.5	5.0	10
0	0.61% \pm 0.11	0.32% \pm 0.12	0.48% \pm 0.33	0.65% \pm 0.12
2.5	2.31% \pm 0.66	1.26% \pm 0.61	0.89% \pm 0.36	0.72% \pm 0.55
5.0	11.2% \pm 3.25	2.11% \pm 0.33 ^b	0.94% \pm 0.47 ^b	1.06% \pm 0.42 ^b
10	23.1% \pm 4.86	3.12% \pm 1.22 ^c	2.49% \pm 0.12 ^c	1.88% \pm 0.50 ^c

^aData represent percent migrating LSK BM cells.

^b $p < 0.01$ when compared with group that had 0 nM rmDEK in top chamber and 5.0 nM rhSDF1 α in bottom chamber.

^c $p < 0.01$ when compared with group that had 0 nM rmDEK in top chamber and 10 nM rhSDF1 α in bottom chamber.

TABLE 4 Checkerboard assay to determine if rhSDF1 α can inhibit the migration of LSK BM cells toward rmDEK (see Figure S2(D) for experimental design)^a

rmDEK concentration (nM) in lower chamber	rhSDF1 α concentration (nM) in upper chamber			
	0	2.5	5.0	10.0
0	0.53% \pm 0.23	0.49% \pm 0.10	0.36% \pm 0.09	0.86% \pm 0.66
2.5	19.8% \pm 2.45	14.7% \pm 1.28 ^b	9.86% \pm 3.67 ^b	1.36% \pm 0.64 ^b
5.0	21.3% \pm 3.48	15.6% \pm 2.39 ^c	10.1% \pm 2.81 ^c	3.32% \pm 0.44 ^c
10.0	18.6% \pm 2.71	20.1% \pm 3.45	19.4% \pm 6.12	8.44% \pm 2.66 ^d

^aData represent percent migrating LSK BM cells.

^b $p < 0.05$ when compared with group that had 0 nM rhSDF1 α in top chamber and 2.5 nM rmDEK in bottom chamber.

^c $p < 0.05$ when compared with group that had 0 nM rhSDF1 α in top chamber and 5.0 nM rmDEK in bottom chamber.

^d $p < 0.01$ when compared with group that had 0 nM rhSDF1 α in top chamber and 10 nM rmDEK in bottom chamber.

chemotactic actions through a CXCR2-dependent mechanism. First, CXCR2 expression was examined in various subpopulations of human and mouse hematopoietic cells utilizing the publicly available microarray data compiled by BloodSpot database.^{28–36} These analyses revealed that while there is generally more CXCR2 RNA expressed in mature myeloid cells and HPC populations, CXCR2 is also expressed at detectable levels in human HSC and mouse LT-HSC and ST-HSC (Figure S3). Next, we performed migration assays where LSK cells were pretreated with neutralizing monoclonal antibody for CXCR2 immediately prior to being placed in the upper chamber of a transwell chemotaxis assay utilizing 100 ng/ml of rmDEK in the bottom chamber. Ly6G⁺ cells (neutrophils) were utilized as a positive control as they migrate toward SDF1 α via CXCR4, MIP2 via CXCR2, IL-8 via CXCR1/CXCR2 and DEK.^{9,37–40} Neutralizing anti-CXCR2 antibodies inhibited migration of

both LSK and Ly6G⁺ cells toward rmDEK; however, if LSK cells were pretreated with an isotype control or a neutralizing antibody toward CXCR4, migration toward DEK was not blocked (Figure 2(A)). To confirm that the neutralizing CXCR2 antibody did not inhibit migration in a nonspecific manner, transwell assays were performed examining LSK cell migration toward rhSDF1 α , rhIL-8, and rmMIP2. LSK cells were still able to migrate toward rhSDF1 α except when CXCR4 was neutralized. As previously reported, no migration of LSK cells was observed when IL-8 or MIP2 was utilized.^{41,42} When Ly6G⁺ neutrophils were used, CXCR2 neutralizing antibodies blocked migration of the Ly6G⁺ neutrophils toward rmDEK, rhIL-8, and rmMIP2 (Figure 2(B)). Neutralizing CXCR4 only blocked Ly6G⁺ neutrophil migration toward rhSDF1 α . Chemokine receptors couple to G proteins for signal transduction and this interaction can be blocked using PT, which prevents G α i proteins




FIGURE 2 DEK-induced migration of LSK and Ly6G⁺ cells is dependent on CXCR2 and G α i protein-coupled signaling. (A and B) BM Lin⁻ or Ly6G⁺ cells were treated with anti-rat IgG (isotype), anti-CXCR2, or anti-CXCR4 neutralizing antibody prior to being placed in the top chamber of a transwell plate and allowed to migrate toward 100 ng/ml rhSDF1 α , rmDEK, rhIL-8, or rmMIP2 for 4 h at 37°C. Total LSK (A) or Ly6G⁺ (B) cell migration was determined using flow cytometry with background migration subtracted from total migrated cells. (C and D) BM Lin⁻ or Ly6G⁺ cells were treated with 1000 ng/ml Pertussis toxin (PT) for 4 h at 37°C prior to being placed in the top chamber of a transwell plate and allowed to migrate toward 100 ng/ml rhSDF1 α , rmDEK, rhIL-8, or rmMIP2 for 4 h at 37°C. Total LSK (C) or Ly6G⁺ (D) cell migration was determined using flow cytometry with background migration subtracted from total migrated cells. (A–D) Data are the mean \pm SD of triplicate wells. Data are representative of 1 of 3 separate experiments. * p < 0.05, ** p < 0.01, and *** p < 0.001 when compared with control for the given chemokine/recombinant protein

from interacting with G protein-coupled receptors and thus interfering with receptor signaling.⁴³ Pretreatment of LSK cells with PT significantly inhibited migration of LSK cells toward rmDEK and rhSDF1 α (Figure 2(C)). Pretreatment of Ly6G⁺ neutrophils with PT resulted in significant reduction in migration toward rhSDF1 α , rmDEK, rhIL-8, and rmMIP2 (Figure 2(D)). These data taken together demonstrate that LSK cell-directed migration toward rmDEK is CXCR2- and G protein-coupled signaling dependent.

We now demonstrate that extracellular DEK induces LSK cell (e.g., LT-HSC, ST-HSC, and MPP) migration in a dose- and time-dependent, chemotactic manner. It is striking that this nuclear protein, when extracellular, can have such profound effects not only in regulating hematopoiesis,^{14–16} but by acting as a chemotactic agent for HSC/HPC as well. Like other chemokines (e.g., IL-8 and MIP2), DEK suppresses functional HPC numbers in a CXCR2-dependent manner.^{16,44–47} DEK-mediated enhancement in HSC numbers in vivo and ex vivo is also dependent on CXCR2.¹⁶ However, unlike the other chemokines whose function is dependent on CXCR2, DEK requires G α i protein coupled signaling to mediate its effect on hematopoiesis.^{16,43,47} CXCR4 requires G α i protein-coupled signaling for HSC/HPC migration toward SDF1 α as well as providing SDF1 α prosurvival signals to myeloid progenitor cells in colony assays.⁴³ LSK cell migration toward DEK is CXCR2- and G α i protein-coupled signaling dependent. It is possible that DEK induces HSC/HPC migration because it functions through a G α i protein-coupled-mediated mechanism like SDF1 α . However, IL-8 and MIP2 do not induce migration of HSC/HPC, possibly because

their hematopoietic function does not require G α i protein-coupled signaling for these immature hematopoietic cell populations. This matter requires further investigation.

DEK competes with SDF1 α as a chemoattractant agent for LSK cells (Tables 3 and 4). From these assays, it was clear that rmDEK was a more potent chemoattractant for mouse BM LSK cells than rhSDF1 α . Interestingly in our previous publication,¹⁶ we reported that in vivo treatment with rmDEK resulted in a temporary decrease in CXCR4 (the receptor for SDF1 α) expression in LSK, LK and HSC populations, which resulted in decreased homing of these cell populations to the BM following an 18-h homing assay in lethally irradiated mice. The mechanism of how DEK alters CXCR4 expression on HSC/HPC populations remains unknown. In the case of HSC, HPC, and neutrophils, the SDF1 α :CXCR4 axis is an important retention signal for these cells to remain in the BM.²³ However, multiple inflammatory signals can disrupt this axis. For example, neutrophil egress from the BM is induced by inflammatory stress conditions (e.g., infection and tissue damage) relying on keratinocyte-derived chemokine, MIP2, IL-8, or the GRO proteins: CXCR2 signaling.^{23,39,48,49} Cxcr2-deficient mice selectively retain neutrophils in the BM and exhibit neutropenia in circulation.^{23,40} Is it possible that DEK secretion, which is induced under inflammatory conditions,^{2,9,11} might disrupt the retention signal for HSC, HPC, and/or neutrophils? Our data suggest that DEK might be involved as a possible compensatory chemotactic agent for HSCs and HPCs under stress/inflammation when SDF1 α signaling is reduced.

AUTHORSHIP

M. L. C., Y. S., J. R., N. M., M. L., and D. M. M. conceived the research, designed and performed experiments, interpreted data, and wrote the manuscript.

ACKNOWLEDGMENTS

The authors would like to acknowledge the contributions to this research by Hal E. Broxmeyer who passed away prior to the acceptance of this manuscript. H. E. B. helped conceive the research, design, and perform the experiments, interpret data, and helped to write the manuscript. These studies were supported by US Public Health Service grants from the NIH R01 DK 109188 to H. E. B., D. M. M., and M. L. C., U54 DK 106846 to H. E. B., T32 DK 007519 to J. R. (PI H. E. B.), and R35 HL 139599 to H. E. B. Additional grant support to M. L. C. and H. E. B. was provided by the Indiana Clinical and Translational Sciences Institute (CTSI) core pilot grant program. Grant support to M. L. C. was provided by Indiana University Simon Cancer Center American Cancer Society Institutional Research Pilot Grant IRG-16-192-31.

DISCLOSURES

N. M.-V. and D. M. M. are coinventors on a patent for an aptamer that blocks DEK function. All other authors (M. L. C., Y. S., J. R., M. L., and H. E. B.) have nothing to disclose.

REFERENCES

- Kappes F, Waldmann T, Mathew V, et al. The DEK oncoprotein is a Su(var) that is essential to heterochromatin integrity. *Genes Dev.* 2011;25:673-678.
- Capitano ML, Broxmeyer HE. A role for intracellular and extracellular DEK in regulating hematopoiesis. *Curr Opin Hematol.* 2017;24:300-306.
- Waldmann T, Baack M, Richter N, Gruss C. Structure-specific binding of the proto-oncogene protein DEK to DNA. *Nucleic Acids Res.* 2003;31:7003-7010.
- Sawatsubashi S, Murata T, Lim J, et al. A histone chaperone, DEK, transcriptionally coactivates a nuclear receptor. *Genes Dev.* 2010;24:159-170.
- Kappes F, Damoc C, Knippers R, Przybylski M, Pinna LA, Gruss C. Phosphorylation by protein kinase CK2 changes the DNA binding properties of the human chromatin protein DEK. *Mol Cell Biol.* 2004;24:6011-6020.
- Gamble MJ, Fisher RP. SET and PARP1 remove DEK from chromatin to permit access by the transcription machinery. *Nat Struct Mol Biol.* 2007;14:548-555.
- Kappes F, Fahrer J, Khodadoust MS, et al. DEK is a poly(ADP-ribose) acceptor in apoptosis and mediates resistance to genotoxic stress. *Mol Cell Biol.* 2008;28:3245-3257.
- Saha AK, Kappes F, Mundade A, et al. Intercellular trafficking of the nuclear oncoprotein DEK. *Proc Natl Acad Sci USA.* 2013;110:6847-6852.
- Mor-Vaknin N, Punturieri A, Sitwala K, et al. The DEK nuclear autoantigen is a secreted chemotactic factor. *Mol Cell Biol.* 2006;26:9484-9496.
- Dong X, Michelis MA, Wang J, Bose R, DeLange T, Reeves WH. Autoantibodies to DEK oncoprotein in a patient with systemic lupus erythematosus and sarcoidosis. *Arthritis Rheum.* 1998;41:1505-1510.
- Mor-Vaknin N, Saha A, Legendre M, et al. Markovitz, D.M. DEK-targeting DNA aptamers as therapeutics for inflammatory arthritis. *Nat Commun.* 2017;8:14252.
- Mor-Vaknin N, Kappes F, Dick AE, et al. DEK in the synovium of patients with juvenile idiopathic arthritis: characterization of DEK antibodies and posttranslational modification of the DEK autoantigen. *Arthritis Rheum.* 2011;63:556-567.
- Logan GE, Mor-Vaknin N, Braunschweig T, et al. DEK oncogene expression during normal hematopoiesis and in Acute Myeloid Leukemia (AML). *Blood Cells Mol Dis.* 2015;54:123-131.
- Broxmeyer HE, Kappes F, Mor-Vaknin N, et al. DEK regulates hematopoietic stem engraftment and progenitor cell proliferation. *Stem Cells Dev.* 2012;21:1449-1454.
- Broxmeyer HE, Mor-Vaknin N, Kappes F, et al. Concise review: role of DEK in stem/progenitor cell biology. *Stem Cells.* 2013;31:1447-1453.
- Capitano ML, Mor-Vaknin N, Saha AK, et al. Secreted nuclear protein DEK regulates hematopoiesis through CXCR2 signaling. *J Clin Invest.* 2019;129:2555-2570.
- Koleva RI, Ficarro SB, Radomska HS, et al. C/EBPalpha and DEK coordinately regulate myeloid differentiation. *Blood.* 2012;119:4878-4888.
- Lohmann F, Dangeti M, Soni S, et al. The DEK oncoprotein is a critical component of the EKLF/KLF1 enhancer in erythroid cells. *Mol Cell Biol.* 2015;35:3726-3738.
- Siatecka M, Bieker JJ. The multifunctional role of EKLF/KLF1 during erythropoiesis. *Blood.* 2011;118:2044-2054.
- Tallack MR, Whittington T, Yuen WS, et al. A global role for KLF1 in erythropoiesis revealed by ChIP-seq in primary erythroid cells. *Genome Res.* 2010;20:1052-1063.
- Yien YY, Bieker JJ. EKLF/KLF1, a tissue-restricted integrator of transcriptional control, chromatin remodeling, and lineage determination. *Mol Cell Biol.* 2013;33:4-13.
- Lim SK, Bieker JJ, Lin CS, Costantini F. A shortened life span of EKLF-/- adult erythrocytes, due to a deficiency of beta-globin chains, is ameliorated by human gamma-globin chains. *Blood.* 1997;90:1291-1299.
- Capitano ML, Broxmeyer HE. CXCL12/SDF-1 and hematopoiesis. In: Bradshaw RA and Stahl PD, eds. *Encyclopedia of Cell Biology*. Editors. Elsevier Publishing; 2016:624-631.
- Kim CH, Broxmeyer HE. In vitro behavior of hematopoietic progenitor cells under the influence of chemoattractants: stromal cell-derived factor-1, steel factor, and the bone marrow environment. *Blood.* 1998;91:100-110.
- Strieter RM, Polverini PJ, Kunkel SL, et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. *J Biol Chem.* 1995;270:27348-27357.
- Broxmeyer HE, Capitano M, Campbell TB, Hangoc G, Cooper S. Modulation of hematopoietic chemokine effects in vitro and in vivo by DPP-4/CD26. *Stem Cells Dev.* 2016;25:575-585.
- Broxmeyer HE, Cooper S, Cacalano G, Hague NL, Bailish E, Moore MW. Involvement of Interleukin (IL) 8 receptor in negative regulation of myeloid progenitor cells in vivo: evidence from mice lacking the murine IL-8 receptor homologue. *J Exp Med.* 1996;184:1825-1832.
- Bagger FO, Sasivarevic D, Sohi SH, et al. BloodSpot: a database of gene expression profiles and transcriptional programs for healthy and malignant haematopoiesis. *Nucleic Acids Res.* 2016;44:D917-924.
- Di Tullio A, Vu Manh TP, Schubert A, Castellano G, Månsson R, Graf T. CCAAT/enhancer binding protein alpha (C/EBP(alpha))-induced transdifferentiation of pre-B cells into macrophages involves no overt retrodifferentiation. *Proc Natl Acad Sci USA.* 2011;108:17016-17021.
- Chambers SM, Boles NC, Lin KY, et al. Hematopoietic fingerprints: an expression database of stem cells and their progeny. *Cell Stem Cell.* 2007;1:578-591.
- Berg JS, Lin KK, Sonnet C, et al. Imprinted genes that regulate early mammalian growth are coexpressed in somatic stem cells. *PLoS One.* 2011;6:e26410.
- Majeti R, Becker MW, Tian Q, et al. Dysregulated gene expression networks in human acute myelogenous leukemia stem cells. *Proc Natl Acad Sci USA.* 2009;106:3396-3401.

33. Andersson A, Edén P, Olofsson T, Fioretos T. Gene expression signatures in childhood acute leukemias are largely unique and distinct from those of normal tissues and other malignancies. *BMC Med Genomics*. 2010;3:6.
34. Hu X, Chung AY, Wu I, et al. Integrated regulation of Toll-like receptor responses by Notch and interferon-gamma pathways. *Immunity*. 2008;29:691-703.
35. Schinke C, Giricz O, Li W, Shastri A, et al. IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells. *Blood*. 2015;125:3144-3152.
36. Sinclair A, Park L, Shah M, et al. CXCR2 and CXCL4 regulate survival and self-renewal of hematopoietic stem/progenitor cells. *Blood*. 2016;128:371-383.
37. Sadik CD, Kim ND, Luster AD. Neutrophils cascading their way to inflammation. *Trends Immunol*. 2011;32:452-460.
38. Suratt BT, Petty JM, Young SK, et al. Role of the CXCR4/SDF-1 chemokine axis in circulating neutrophil homeostasis. *Blood*. 2004;104:565-571.
39. Wengner AM, Pitchford SC, Furze RC, Rankin SM. The coordinated action of G-CSF and ELR+ CXC chemokines in neutrophil mobilization during acute inflammation. *Blood*. 2008;111:42-49.
40. Eash KJ, Greenbaum AM, Gopalan PK, Link DC. CXCR2 and CXCR4 antagonistically regulate neutrophil trafficking from murine bone marrow. *J Clin Invest*. 2010;120:2423-2431.
41. Wright DE, Bowman EP, Wagers AJ, Butcher EC, Weissman IL. Hematopoietic stem cells are uniquely selective in their migratory response to chemokines. *J Exp Med*. 2002;195:1145-1154.
42. Pelus LM, Fukuda S. Peripheral blood stem cell mobilization: the CXCR2 ligand GRObeta rapidly mobilizes hematopoietic stem cells with enhanced engraftment properties. *Exp Hematol*. 2006;34:1010-1020.
43. Broxmeyer HE, Youn BS, Kim C, Hangoc G, Cooper S, Mantel C. Chemokine regulation of hematopoiesis and the involvement of pertussis toxin-sensitive G alpha i proteins. *Ann N Y Acad Sci*. 2001;938:117-128.
44. Broxmeyer HE, Cooper S, Hague N, et al. Human chemokines: enhancement of specific activity and effects in vitro on normal and leukemic progenitors and a factor-dependent cell line and in vivo in mice. *Ann Hematol*. 1995;71:235-246.
45. Broxmeyer HE, Kim CH. Regulation of hematopoiesis in a sea of chemokine family members with a plethora of redundant activities. *Exp Hematol*. 1999;27:1113-1123.
46. Daly TJ, LaRosa GJ, Dolich S, Maione TE, Cooper S, Broxmeyer HE. High activity suppression of myeloid progenitor proliferation by chimeric mutants of interleukin 8 and platelet factor 4. *J Biol Chem*. 1995;270:23282-23292.
47. Broxmeyer HE. Regulation of hematopoiesis by chemokine family members. *Int J Hematol*. 2001;74:9-17.
48. Burdon PC, Martin C, Rankin SM. The CXC chemokine MIP-2 stimulates neutrophil mobilization from the rat bone marrow in a CD49-dependent manner. *Blood*. 2005;105:2543-2548.
49. Burdon PC, Martin C, Rankin SM. Migration across the sinusoidal endothelium regulates neutrophil mobilization in response to ELR+ CXC chemokines. *Br J Haematol*. 2008;142:100-108.

SUPPORTING INFORMATION

Additional supporting information may be found in the online version of the article at the publisher's website.

How to cite this article: Capitano ML, Sasmour Y, Ropa J, Legendre M, Mor-Vaknin N, Markovitz DM. DEK, a nuclear protein, is chemotactic for hematopoietic stem/progenitor cells acting through CXCR2 and G α i signaling. *J Leukoc Biol*. 2022;112:449-456.

<https://doi.org/10.1002/JLB.3AB1120-740R>